<?xml version='1.0' encoding='utf-8'?>
<document id="26158794"><sentence text="A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs."><entity charOffset="65-78" id="DDI-PubMed.26158794.s1.e0" text="Tofogliflozin" /></sentence><sentence text="Tofogliflozin is an oral hypoglycemic agent with a novel mechanism of action that reduces blood glucose levels by promoting glucose excretion in urine, achieved by selectively inhibiting sodium-glucose co-transporter 2 (SGLT2)"><entity charOffset="0-13" id="DDI-PubMed.26158794.s2.e0" text="Tofogliflozin" /><entity charOffset="96-103" id="DDI-PubMed.26158794.s2.e1" text="glucose" /><entity charOffset="124-131" id="DDI-PubMed.26158794.s2.e2" text="glucose" /><pair ddi="false" e1="DDI-PubMed.26158794.s2.e0" e2="DDI-PubMed.26158794.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26158794.s2.e0" e2="DDI-PubMed.26158794.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26158794.s2.e0" e2="DDI-PubMed.26158794.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26158794.s2.e1" e2="DDI-PubMed.26158794.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26158794.s2.e1" e2="DDI-PubMed.26158794.s2.e2" /></sentence><sentence text=" We evaluated the effects of several selected anti-type 2 diabetes mellitus (T2DM) drugs-glimepiride, metformin, sitagliptin, pioglitazone, miglitol, nateglinide, and voglibose-on the pharmacokinetics and pharmacodynamics of tofogliflozin, and the effects of tofogliflozin on the pharmacokinetics of these anti-T2DM drugs in healthy male volunteers"><entity charOffset="89-100" id="DDI-PubMed.26158794.s3.e0" text="glimepiride" /><entity charOffset="102-111" id="DDI-PubMed.26158794.s3.e1" text="metformin" /><entity charOffset="113-124" id="DDI-PubMed.26158794.s3.e2" text="sitagliptin" /><entity charOffset="126-138" id="DDI-PubMed.26158794.s3.e3" text="pioglitazone" /><entity charOffset="140-148" id="DDI-PubMed.26158794.s3.e4" text="miglitol" /><entity charOffset="150-161" id="DDI-PubMed.26158794.s3.e5" text="nateglinide" /><entity charOffset="167-176" id="DDI-PubMed.26158794.s3.e6" text="voglibose" /><entity charOffset="225-238" id="DDI-PubMed.26158794.s3.e7" text="tofogliflozin" /><entity charOffset="259-272" id="DDI-PubMed.26158794.s3.e8" text="tofogliflozin" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e0" e2="DDI-PubMed.26158794.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e0" e2="DDI-PubMed.26158794.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e0" e2="DDI-PubMed.26158794.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e0" e2="DDI-PubMed.26158794.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e0" e2="DDI-PubMed.26158794.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e0" e2="DDI-PubMed.26158794.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e0" e2="DDI-PubMed.26158794.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e0" e2="DDI-PubMed.26158794.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e0" e2="DDI-PubMed.26158794.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e1" e2="DDI-PubMed.26158794.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e1" e2="DDI-PubMed.26158794.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e1" e2="DDI-PubMed.26158794.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e1" e2="DDI-PubMed.26158794.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e1" e2="DDI-PubMed.26158794.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e1" e2="DDI-PubMed.26158794.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e1" e2="DDI-PubMed.26158794.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e1" e2="DDI-PubMed.26158794.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e2" e2="DDI-PubMed.26158794.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e2" e2="DDI-PubMed.26158794.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e2" e2="DDI-PubMed.26158794.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e2" e2="DDI-PubMed.26158794.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e2" e2="DDI-PubMed.26158794.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e2" e2="DDI-PubMed.26158794.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e2" e2="DDI-PubMed.26158794.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e3" e2="DDI-PubMed.26158794.s3.e3" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e3" e2="DDI-PubMed.26158794.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e3" e2="DDI-PubMed.26158794.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e3" e2="DDI-PubMed.26158794.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e3" e2="DDI-PubMed.26158794.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e3" e2="DDI-PubMed.26158794.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e4" e2="DDI-PubMed.26158794.s3.e4" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e4" e2="DDI-PubMed.26158794.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e4" e2="DDI-PubMed.26158794.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e4" e2="DDI-PubMed.26158794.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e4" e2="DDI-PubMed.26158794.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e5" e2="DDI-PubMed.26158794.s3.e5" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e5" e2="DDI-PubMed.26158794.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e5" e2="DDI-PubMed.26158794.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e5" e2="DDI-PubMed.26158794.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e6" e2="DDI-PubMed.26158794.s3.e6" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e6" e2="DDI-PubMed.26158794.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e6" e2="DDI-PubMed.26158794.s3.e8" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e7" e2="DDI-PubMed.26158794.s3.e7" /><pair ddi="false" e1="DDI-PubMed.26158794.s3.e7" e2="DDI-PubMed.26158794.s3.e8" /></sentence><sentence text="" /><sentence text="A single dose of either tofogliflozin alone, one of the anti-T2DM drugs alone, or co-administration of tofogliflozin and the anti-T2DM drug was administered to 108 healthy men"><entity charOffset="24-37" id="DDI-PubMed.26158794.s5.e0" text="tofogliflozin" /><entity charOffset="103-116" id="DDI-PubMed.26158794.s5.e1" text="tofogliflozin" /><pair ddi="false" e1="DDI-PubMed.26158794.s5.e0" e2="DDI-PubMed.26158794.s5.e0" /><pair ddi="false" e1="DDI-PubMed.26158794.s5.e0" e2="DDI-PubMed.26158794.s5.e1" /></sentence><sentence text=" Cmax, AUCinf, and cumulative urine glucose excretion after co-administration of tofogliflozin and each of the anti-T2DM drugs was evaluated relative to the values of those parameters after administration of each drug alone"><entity charOffset="36-43" id="DDI-PubMed.26158794.s6.e0" text="glucose" /><entity charOffset="81-94" id="DDI-PubMed.26158794.s6.e1" text="tofogliflozin" /><pair ddi="false" e1="DDI-PubMed.26158794.s6.e0" e2="DDI-PubMed.26158794.s6.e0" /><pair ddi="false" e1="DDI-PubMed.26158794.s6.e0" e2="DDI-PubMed.26158794.s6.e1" /></sentence><sentence text="" /><sentence text="None of the anti-T2DM drugs had any effect on tofogliflozin exposure"><entity charOffset="46-59" id="DDI-PubMed.26158794.s8.e0" text="tofogliflozin" /></sentence><sentence text=" Tofogliflozin had no or little effect on the exposure of any anti-T2DM drug"><entity charOffset="1-14" id="DDI-PubMed.26158794.s9.e0" text="Tofogliflozin" /></sentence><sentence text=" No anti-T2DM drug had any major effect on the cumulative urine glucose excretion induced by tofogliflozin"><entity charOffset="64-71" id="DDI-PubMed.26158794.s10.e0" text="glucose" /><entity charOffset="93-106" id="DDI-PubMed.26158794.s10.e1" text="tofogliflozin" /><pair ddi="false" e1="DDI-PubMed.26158794.s10.e0" e2="DDI-PubMed.26158794.s10.e0" /><pair ddi="false" e1="DDI-PubMed.26158794.s10.e0" e2="DDI-PubMed.26158794.s10.e1" /></sentence><sentence text=" There were no safety concerns evident after administration of any drug alone or in co-administration" /><sentence text="" /><sentence text="Neither the pharmacokinetics nor the pharmacodynamics of tofogliflozin was affected by any of the anti-T2DM drugs evaluated in this study, nor was the pharmacokinetics of any of the anti-T2DM drugs affected by tofogliflozin in healthy male volunteers"><entity charOffset="57-70" id="DDI-PubMed.26158794.s13.e0" text="tofogliflozin" /><entity charOffset="210-223" id="DDI-PubMed.26158794.s13.e1" text="tofogliflozin" /><pair ddi="false" e1="DDI-PubMed.26158794.s13.e0" e2="DDI-PubMed.26158794.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26158794.s13.e0" e2="DDI-PubMed.26158794.s13.e1" /></sentence><sentence text="" /></document>